跳至主要内容
临床试验/DRKS00028931
DRKS00028931招募中不适用

A registry to collect characteristics and outcomes from patients with solid tumors profiled with a next-generation sequencing test (WAYFIND-R) - WAYFIND-R, MX39897

F. Hoffmann-La Roche Ltd.0 个研究点目标入组 15,000 人开始时间: 2022年5月25日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
15,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • The registry population will include adult patients who are diagnosed with solid tumor cancers (at
  • any anatomical location) and at any stage of the disease. Both male and female patients will be
  • included in this registry.
  • Patients must meet the following criteria for enrolment in this registry:
  • - Patient is an adult (according to age of majority as defined by local regulations)
  • - Patient is currently diagnosed with any type of solid tumor cancer, at any stage of the
  • disease, at the enrolment date (informed consent date)
  • - Patient has undergone NGS testing, no longer than 3 months prior to the enrolment date,
  • irrespective of the availability of test results
  • - Informed consent has been obtained from the patient or legally authorized representative,
  • as per local regulations

排除标准

  • Patients who meet the below exclusion criterion at the time of enrolment will not be enrolled in
  • this registry:
  • - Patient has a prior or current diagnosis of hematological malignancy

研究者

相似试验